178 related articles for article (PubMed ID: 25113440)
1. Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.
Walia V; Prickett TD; Kim JS; Gartner JJ; Lin JC; Zhou M; Rosenberg SA; Elble RC; Solomon DA; Waldman T; Samuels Y
Hum Mutat; 2014 Nov; 35(11):1301-10. PubMed ID: 25113440
[TBL] [Abstract][Full Text] [Related]
2. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma.
Solomon DA; Kim JS; Cronin JC; Sibenaller Z; Ryken T; Rosenberg SA; Ressom H; Jean W; Bigner D; Yan H; Samuels Y; Waldman T
Cancer Res; 2008 Dec; 68(24):10300-6. PubMed ID: 19074898
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
Veeriah S; Brennan C; Meng S; Singh B; Fagin JA; Solit DB; Paty PB; Rohle D; Vivanco I; Chmielecki J; Pao W; Ladanyi M; Gerald WL; Liau L; Cloughesy TC; Mischel PS; Sander C; Taylor B; Schultz N; Major J; Heguy A; Fang F; Mellinghoff IK; Chan TA
Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9435-40. PubMed ID: 19478061
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene.
Meehan M; Parthasarathi L; Moran N; Jefferies CA; Foley N; Lazzari E; Murphy D; Ryan J; Ortiz B; Fabius AW; Chan TA; Stallings RL
Mol Cancer; 2012 Feb; 11():6. PubMed ID: 22305495
[TBL] [Abstract][Full Text] [Related]
5. IL-6 induces tumor suppressor protein tyrosine phosphatase receptor type D by inhibiting miR-34a to prevent IL-6 signaling overactivation.
Zhang F; Wang B; Qin T; Wang L; Zhang Q; Lu Y; Song B; Yu X; Li L
Mol Cell Biochem; 2020 Oct; 473(1-2):1-13. PubMed ID: 32602014
[TBL] [Abstract][Full Text] [Related]
6. Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications.
Jiang Y; Janku F; Subbiah V; Angelo LS; Naing A; Anderson PM; Herzog CE; Fu S; Benjamin RS; Kurzrock R
Oncotarget; 2013 Jun; 4(6):884-9. PubMed ID: 23800680
[TBL] [Abstract][Full Text] [Related]
7. Reduced expression of PTPRD correlates with poor prognosis in gastric adenocarcinoma.
Wang D; Wang L; Zhou J; Pan J; Qian W; Fu J; Zhang G; Zhu Y; Liu C; Wang C; Jin Z; He Z; Wu J; Shi B
PLoS One; 2014; 9(11):e113754. PubMed ID: 25412184
[TBL] [Abstract][Full Text] [Related]
8. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis.
Ortiz B; Fabius AW; Wu WH; Pedraza A; Brennan CW; Schultz N; Pitter KL; Bromberg JF; Huse JT; Holland EC; Chan TA
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8149-54. PubMed ID: 24843164
[TBL] [Abstract][Full Text] [Related]
9. Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer.
Peyser ND; Du Y; Li H; Lui V; Xiao X; Chan TA; Grandis JR
PLoS One; 2015; 10(8):e0135750. PubMed ID: 26267899
[TBL] [Abstract][Full Text] [Related]
10. High resolution ArrayCGH and expression profiling identifies PTPRD and PCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma.
Giefing M; Zemke N; Brauze D; Kostrzewska-Poczekaj M; Luczak M; Szaumkessel M; Pelinska K; Kiwerska K; Tönnies H; Grenman R; Figlerowicz M; Siebert R; Szyfter K; Jarmuz M
Genes Chromosomes Cancer; 2011 Mar; 50(3):154-66. PubMed ID: 21213369
[TBL] [Abstract][Full Text] [Related]
11. Manipulating PTPRD function with ectodomain antibodies.
Qian Z; Song D; Ipsaro JJ; Bautista C; Joshua-Tor L; Yeh JT; Tonks NK
Genes Dev; 2023 Aug; 37(15-16):743-759. PubMed ID: 37669874
[TBL] [Abstract][Full Text] [Related]
12. Recurrent epigenetic silencing of the PTPRD tumor suppressor in laryngeal squamous cell carcinoma.
Szaumkessel M; Wojciechowska S; Janiszewska J; Zemke N; Byzia E; Kiwerska K; Kostrzewska-Poczekaj M; Ustaszewski A; Jarmuz-Szymczak M; Grenman R; Wierzbicka M; Bartochowska A; Szyfter K; Giefing M
Tumour Biol; 2017 Mar; 39(3):1010428317691427. PubMed ID: 28345455
[TBL] [Abstract][Full Text] [Related]
13. Lack of inherited mutations of PTPRD in familial melanoma and melanoma-astrocytoma syndrome.
Solomon DA; Kim JS; Yang XR; Tucker MA; Goldstein AM; Samuels Y; Waldman T
Pigment Cell Melanoma Res; 2009 Aug; 22(4):489-91. PubMed ID: 19500277
[No Abstract] [Full Text] [Related]
14. Loss of Tyrosine Phosphatase Delta Promotes Gastric Cancer Progression via Signal Transducer and Activator of Transcription 3 Pathways.
Wu L; Gao L; Kong D; Xue H
Dig Dis Sci; 2019 Nov; 64(11):3164-3172. PubMed ID: 31041642
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction.
Matsui Y; Imai A; Izumi H; Yasumura M; Makino T; Shimizu T; Sato M; Mori H; Yoshida T
FASEB J; 2024 Apr; 38(7):e23609. PubMed ID: 38593345
[TBL] [Abstract][Full Text] [Related]
16. Deletion of Ptprd and Cdkn2a cooperate to accelerate tumorigenesis.
Ortiz B; White JR; Wu WH; Chan TA
Oncotarget; 2014 Aug; 5(16):6976-82. PubMed ID: 25138050
[TBL] [Abstract][Full Text] [Related]
17. A catalog of genes homozygously deleted in human lung cancer and the candidacy of PTPRD as a tumor suppressor gene.
Kohno T; Otsuka A; Girard L; Sato M; Iwakawa R; Ogiwara H; Sanchez-Cespedes M; Minna JD; Yokota J
Genes Chromosomes Cancer; 2010 Apr; 49(4):342-52. PubMed ID: 20073072
[TBL] [Abstract][Full Text] [Related]
18. The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis.
Tomita H; Cornejo F; Aranda-Pino B; Woodard CL; Rioseco CC; Neel BG; Alvarez AR; Kaplan DR; Miller FD; Cancino GI
Cell Rep; 2020 Jan; 30(1):215-228.e5. PubMed ID: 31914388
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.
Henderson IM; Zeng F; Bhuiyan NH; Luo D; Martinez M; Smoake J; Bi F; Perera C; Johnson D; Prisinzano TE; Wang W; Uhl GR
Biochem Pharmacol; 2022 Jan; 195():114868. PubMed ID: 34863978
[TBL] [Abstract][Full Text] [Related]
20. Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.
Lambert SR; Harwood CA; Purdie KJ; Gulati A; Matin RN; Romanowska M; Cerio R; Kelsell DP; Leigh IM; Proby CM
Int J Cancer; 2012 Aug; 131(3):E216-26. PubMed ID: 22052591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
